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ARTICLE

Higher risk for incident heart failure and
cardiovascular mortality among community-dwelling
octogenarians without pneumococcal vaccination
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Abstract
Aims Octogenarians have the highest incidence of heart failure (HF) that is not fully explained by traditional risk factors. We
explored whether lack of pneumococcal vaccination is associated with higher risk of incident HF among octogenarians.
Methods and results In the Cardiovascular Health Study (CHS), 5290 community-dwelling adults, ≥65 years of age, were free
of baseline HF and had data on pneumococcal vaccination. Of these, 851 were octogenarians, of whom, 593 did not receive
pneumococcal vaccination. Multivariable-adjusted hazard ratios (aHR) and 95% conﬁdence intervals (CI) for associations of
lack of pneumococcal vaccination with incident HF and other outcomes during 13 years of follow-up were estimated using
Cox regression models, adjusting for demographics and other HF risk factors including inﬂuenza vaccination. Octogenarians
had a mean (±SD) age of 83 (±3) years; 52% were women and 17% African American. Overall, 258 participants developed
HF and 662 died. Lack of pneumococcal vaccination was associated with higher relative risk of incident HF (aHR, 1.37; 95%
CI, 1.01–1.85; P = 0.044). There was also higher risk for all-cause mortality (aHR, 1.23; 95% CI, 1.02–1.49; P = 0.028), which
was mostly driven by cardiovascular mortality (aHR, 1.45; 95% CI, 1.06–1.98; P = 0.019). Octogenarians without pneumococcal
vaccination had a trend toward higher risk of hospitalization due to pneumonia (aHR, 1.34; 95% CI, 0.99–1.81; P = 0.059).
These associations were not observed among those 65–79 years of age.
Conclusions Among community-dwelling octogenarians, lack of pneumococcal vaccination was associated with a signiﬁcantly higher independent risk of incident HF and mortality, and trend for higher pneumonia hospitalization.
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Introduction
Octogenarians are among the fastest growing segments of
the US population, and they also have the highest
incidence of heart failure (HF).1–3 However, traditional risk
factors for incident HF do not appear to explain this
incidence as their impact appears to attenuate with
ageing.4–7 For example, in the Cardiovascular Health Study
(CHS), among those <78 years of age, 18% and 13% of

those with and without isolated systolic hypertension
(ISH) developed new HF, respectively, which corresponded
with a 44% higher relative risk for those with ISH.4 In
contrast, among those ≥78 years of age, 24% and 25%
of those with and without ISH developed new HF.
Similarly, isolated diastolic hypertension was associated
with a 33% signiﬁcantly higher independent risk of
incident HF, which was only observed among those
<75 years of age.5

© 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
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Thus, there is a need to identify non-traditional risk factors
for incident HF among the oldest old who have the highest
incidence of HF that is not well explained by traditional risk
factors. In this context, we conducted an exploratory analysis
to determine if lack of pneumococcal vaccination is associated with higher risk of incident HF. Although pneumococcal
infection is a major cause of cardiovascular morbidity,8 it
has been suggested that pneumococcal vaccination may
reduce the risk of cardiovascular events.9,10 Therefore, in
the current study, we examined whether lack of pneumococcal vaccination is associated with higher risk of incident HF in
community-dwelling octogenarians.

Methods
Data source and study participants
We used de-identiﬁed copies of the CHS data obtained from
the National Heart, Lung and Blood Institute (NHLBI), which
also sponsored the study. The rationale and design of the
CHS have been previously reported.11 The CHS is an ongoing,
prospective, community-based epidemiologic study based
on 5888 Medicare-eligible community-dwelling older
adults, aged 65 year and older, from Forsyth County, North
Carolina; Sacramento County, California; Washington County,
Maryland; and Pittsburgh, Pennsylvania. An initial cohort of
5201 participants was recruited between 1989 and 1990,
and a second cohort of 687 African Americans was recruited
between 1992 and 1993. Of the 5888 CHS participants, 5795
consent to be included in the public-use copy of the data.
Of these, 240 without data on baseline pneumococcal vaccination and 265 with baseline prevalent HF were excluded.
Of the remaining 5290, 851 were 80 years and older and
4439 were 65 to 79 years of age at baseline. Data on pneumococcal vaccination were collected at baseline by asking
the questions: ‘Have you ever had a shot to prevent
pneumonia (pneumovax)?’12 Additional data on sociodemographic characteristics, health behaviours, self-rated
health and vaccination history, comorbid conditions, medications, vital signs, markers of inﬂammation, and other biochemical covariates were collected at baseline and have been
previously described in details.11 Missing values for variables
were imputed based on values predicted by age, sex, and race.

Outcomes
Primary outcomes for the current analysis were incident
HF and all-cause mortality during 13 years of follow-up.
Incident HF was centrally adjudicated by the CHS Events
Committee, which has been well described in literature.13
The process began with self-reports of physician-diagnosed
HF, which were then conﬁrmed by review of medical records

for symptoms, signs, medications, and other evidence of HF.4–7
The CHS criteria for HF diagnosis have been shown to be more
stringent than those used in the Framingham Heart Study.14
Secondary outcomes of interest were cardiovascular and
non-cardiovascular mortality, as well as all-cause hospitalization and hospitalization due to pneumonia.

Statistical analysis
For descriptive analyses, we used Pearson’s χ 2 for categorical
variables and analysis of variance for continuous variables.
Kaplan Meier survival analysis was used to determine the association of pneumococcal vaccination with outcomes during
13 years of follow-up. Unadjusted and multivariable-adjusted
Cox regression models were used to estimate the association
of lack of pneumococcal vaccination with outcomes. All statistical tests were two-sided, and tests with P-value <0.05
were considered signiﬁcant. SPSS for Windows (Version 18)
was used for data analysis. We repeated our analysis in
participants 65 to 79 years of age.

Results
Baseline characteristics
Octogenarians had a mean (±SD) age of 83 (±3) years;
52% were female, and 17% were African American. The
distribution of baseline characteristics between participants receiving or not receiving pneumococcal vaccination
was generally balanced (Table 1). A greater proportion of
octogenarians receiving pneumococcal vaccination also
received inﬂuenza vaccination and had higher prevalence
of chronic obstructive pulmonary disease and pneumonia.

Incident heart failure
During 13 years of follow-up, among octogenarians, a
non-receipt of pneumococcal vaccination at baseline was
associated with signiﬁcantly higher risk of incident HF
[adjusted hazard ratio (aHR), 1.37; 95% conﬁdence interval
(CI), 1.01–1.85; Figure 1 and Table 2). In contrast, among
those 65–79 years, a non-use of pneumococcal vaccination
was not associated with incident HF (aHR, 0.88; 95% CI,
0.74–1.04; Table 2).

Mortality
Compared with octogenarians who received pneumococcal
vaccination, non-receipt of pneumococcal vaccination was
associated with signiﬁcantly higher risk of all-cause mortality
ESC Heart Failure 2016; 3: 11–17
DOI: 10.1002/ehf2.12056

58 (23%)
18 (7%)
176 (68%)
32 (12%)
14 (5%)
11 (4%)
19 (7%)
25 (10%)
29 (11%)
49 (19%)
97 (38%)
1.04 (±0.4)
4.0 (±5.7)

124 (21%)
61 (10%)
409 (69%)
92 (16%)
37 (6%)
20 (3%)
46 (8%)
66 (11%)
73 (12%)
46 (8%)
110 (19%)
1.09 (±0.4)
5.1 (±9.1)

0.093
0.072

0.608
0.126
0.827
0.237
0.646
0.524
0.843
0.532
0.659
<0.001
<0.001

0.447
0.136
0.016
0.132
0.108
0.023
0.152
0.939
0.596
0.050
0.253
0.001
<0.001

P-value

0.9 (±0.4)
4.6 (±7.8)

506 (16%)
240 (7%)
1816 (56%)
515 (16%)
99 (3%)
48 (2%)
122 (4%)
214 (7%)
240 (7%)
329 (10%)
765 (23%)

71 (±4)
1943 (59%)
521 (16%)
2293 (70%)
1335 (41%)
1201 (37%)
18 (±27)
41 (±57)
26.8 (±4.0)
0.3 (±0.6)
4.5 (±4.5)
27.8 (±2.4)
979 (30%)

No (n = 3273)

0.9 (±0.5)
4.8 (±9.1)

223 (19%)
98 (8%)
680 (58%)
182 (16%)
54 (5%)
31 (3%)
40 (3%)
80 (7%)
101 (9%)
230 (20%)
436 (37%)

72 (±3)
688 (59%)
134 (12%)
805 (69%)
566 (49%)
519 (45%)
19 (±27)
44 (±57)
26.5 (±4.1)
0.31 (±0.6)
4.5 (±4.3)
28.1 (±2.2)
905 (78%)

Yes (n = 1166)

Pneumococcal vaccination

Age 65–79 years (n = 4439)

CHS, Cardiovascular Health Study; ADL, activities of daily living; COPD, chronic obstructive pulmonary disease; LVH, left ventricular hypertrophy.

83 (±3)
144 (56%)
31 (12%)
145 (56%)
125 (48%)
90 (35%)
14 (±25)
25 (±36)
25.7 (±3.8)
0.7 (±1.0)
5.4 (±4.9)
26.6 (±3.3)
201 (78%)

83 (±3)
298 (50%)
111 (19%)
300 (51%)
252 (43%)
161 (27%)
11 (±24)
25 (±40)
25.5 (±3.9)
0.5 (±0.9)
5.0 (±4.5)
25.7 (±3.9)
225 (38%)

Age, years
Female
African American
Married
Education college or higher
Income ≥$25K
Smoke, pack years
Walk blocks last week
2
Body mass index, kg/m
Instrumental ADL
Centers for Epidemiologic Studies Depression (CES-D) scale score
Mini-Mental State Examination
Flu vaccination
Medical history
Coronary heart diseases
Acute myocardial infarction
Hypertension
Diabetes
Stroke
Atrial ﬁbrillation
LVH by electrocardiogram
LV systolic dysfunction
Left bundle branch block
COPD
Pneumonia
Laboratory data
Serum creatinine, g/dL
Serum C-reactive protein, mg/L

Yes (n = 258)

No (n = 593)

Pneumococcal vaccination

Age ≥80 years (n = 851)

Variables mean (±SD) or n (%)

Table 1 Baseline characteristics by pneumococcal vaccination in CHS

0.902
0.473

0.004
0.236
0.094
0.916
0.010
0.008
0.642
0.704
0.143
0.094
<0.001

<0.001
0.830
<0.001
0.515
<0.001
<0.001
0.351
0.212
0.046
0.073
0.918
0.001
<0.001

P-value

Pneumococcal vaccination and heart failure

13

ESC Heart Failure 2016; 3: 11–17
DOI: 10.1002/ehf2.12056

A. Ahmed et al.

14

Incident heart failure

Figure 1 Multivariable-adjusted risk for incident heart failure among Cardiovascular Health Study participants aged 80 years or older (Hazard ratio
when non-use of pneumococcal vaccination is compared with their use).

Hazard ratio = 1.37;
95% CI = 1.01–1.85;
P = 0.044
No
pneumococcal
vaccine
Pneumococcal
vaccine

Follow-up (years)

(aHR, 1.23; 95% CI, 1.02–1.49), CV mortality (aHR, 1.45; 95%
CI, 1.06–1.98), but not of non-CV mortality (aHR, 1.10; 95%
CI, 0.87–1.40; Table 2). Pneumococcal vaccination had no association with mortality among those 65–79 years of age (Table 3).

Hospitalization
Among octogenarians, non-receipt of pneumococcal vaccination had no association with all-cause hospitalization (aHR,
1.04; 95% CI, 0.87–1.40), but there was a trend toward higher
risk of hospitalization due to pneumonia (aHR, 1.35; 95% CI,
1.00–1.82; Table 2). None of these associations were signiﬁcant among those 65–79 years of age(Table 3).

Discussion
Findings from the current study demonstrated that among
community-dwelling octogenarians, the lack of a prior

pneumococcal vaccination was associated with higher risk
of incident HF and cardiovascular mortality. We also
observed that there was a trend toward higher risk of
hospitalization due to pneumonia. Lack of pneumococcal
vaccination, however, had no association with these outcomes among older adults 65 to 79 years of age. These
ﬁndings are hypothesis generating and suggest that pneumococcal infections may be a non-traditional risk factor
for incident HF among octogenarians, and that pneumococcal vaccination may lower the risk of HF among
octogenarians.
The association of lack of pneumococcal vaccination and
higher incident HF is unlikely to be confounded by other major HF risk factors such as prior myocardial infraction, hypertension, diabetes, and left ventricular systolic dysfunction as
they were similarly distributed at baseline between octogenarians with and without prior pneumococcal vaccination
and we adjusted for those in our multivariable model. They
are also unlikely to be explained by chronic obstructive pulmonary disease and pneumonia as fewer octogenarians not
receiving pneumococcal vaccination had these conditions,
likely explained by the fact that they were potential indications for pneumococcal vaccination.12 Findings from animal
studies suggest that human C-reactive protein (CRP) may protect mice from pneumococcal infection15 and pneumococcal
vaccination is often associated with higher CRP levels.16 Octogenarians without a prior pneumococcal vaccination had
higher CRP levels, and although adjusted for in our multivariable model, residual bias is possible. Inﬂuenza vaccination
has been shown to be associated with lower cardiovascular events.17–20 Octogenarians without pneumococcal vaccination were less likely to receive inﬂuenza vaccination.
Although this was adjusted for, residual bias is possible.
It is also possible that lack of vaccination was a marker
of less healthy life style for octogenarians with no prior
vaccination, which may have contributed to their poor cardiovascular outcomes. However, there was no difference in

Table 2 Association of lack of pneumococcal vaccination with outcomes in octogenarians in the CHS
Events (%)
Pneumococcal vaccination
No (n = 593)
Incident heart failure
All-cause mortality
Cardiovascular
Non-cardiovascular
All-cause hospitalization
Pneumonia

183 (31%)
474 (80%)
201 (34%)
272 (46%)
530 (89%)
184 (31%)

Yes (n = 258)
75
188
68
120
236
75

(29%)
(73%)
(26%)
(47%)
(92%)
(29%)

Hazard ratio* (95% conﬁdence interval); P-value
Unadjusted

Multivariable-adjusted†

1.21 (0.92–1.58); P = 0.165
1.29 (1.09–1.53); P = 0.003
1.50 (1.14–1.98); P = 0.004
1.16 (0.94–1.44); P = 0.168
1.01 (0.87–1.18); P = 0.919
1.20 (0.92–1.57); P = 0.183

1.37 (1.01–1.85); P = 0.044
1.23 (1.02–1.49); P = 0.028
1.45 (1.06–1.98); P = 0.019
1.10 (0.87–1.40); P = 0.426
1.04 (0.87–1.24); P = 0.643
1.35 (1.00–1.82); P = 0.051

CHS, Cardiovascular Health Study.
*Hazard ratio, when non-use of pneumococcal vaccination was compared with their use.
Adjusted for age ≥85 years, sex, race, married, education college or higher, income ≥$25K, smoking ≥32 pack-years, walk blocks last week
2
≥10, body mass index ≥25 kg/m , instrumental activities of daily living ≥1, Centers for Epidemiologic Studies Depression (CES-D) scale
score, Mini-mental state examination (30 item), inﬂuenza vaccination, coronary heart diseases, hypertension, diabetes, stroke, acute
myocardial infarction, atrial ﬁbrillation, left ventricular hypertrophy, left ventricular systolic dysfunction, left bundle branch block, chronic
kidney disease, chronic obstructive pulmonary disease, pneumonia, serum C-reactive protein ≥2.4 mg/L.

†
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CHS, Cardiovascular Health Study.
*Hazard ratio, when non-use of pneumococcal vaccination was compared with their use.
2
†
Adjusted for age ≥70 years, sex, race, married, education college or higher, income ≥$25K, smoking ≥32 pack-years, walk blocks last week ≥10, body mass index ≥25 kg/m , instrumental activities of daily living ≥1, Centers for Epidemiologic Studies Depression (CES-D) scale score, Mini-mental state examination (30 item), inﬂuenza vaccination, coronary heart diseases,
hypertension, diabetes, stroke, acute myocardial infarction, atrial ﬁbrillation, left ventricular hypertrophy, left ventricular systolic dysfunction, bundle branch block, advance chronic
kidney disease, chronic obstructive pulmonary disease, pneumonia, serum C-reactive protein ≥2.4 mg/L

0.88 (0.74–1.04); P = 0.126
0.96 (0.85–1.08); P = 0.480
0.96 (0.79–1.16); P = 0.667
0.95 (0.81–1.10); P = 0.512
0.94 (0.86–1.02); P = 0.111
0.89 (0.75–1.06); P = 0.182
0.78 (0.67–0.91); P = 0.001
0.87 (0.78–0.97); P = 0.009
0.89 (0.75–1.06); P = 0.181
0.85 (0.74–0.97); P = 0.017
0.85 (0.79–0.92); P < 0.001
0.80 (0.69–0.93); P = 0.003
247 (21%)
468 (40%)
187 (16%)
281 (24%)
994 (85%)
246 (21%)
568 (17%)
1182 (36%)
485 (15%)
692 (21%)
2650 (81%)
577 (18%)
Incident heart failure
All-cause mortality
Cardiovascular
Non- cardiovascular
All-cause hospitalization
Pneumonia

Hazard ratio* (95% conﬁdence interval); P-value

Multivariable-adjusted†
Yes (n = 1166)

Pneumococcal vaccination

No (n = 3273)

Events (%)

Table 3 Association of lack of pneumococcal vaccination with outcomes in those 65–79 years of age in the CHS

Unadjusted
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other markers of healthy life style such body mass index
between the two groups suggesting a healthy life style
cannot fully explain our ﬁndings.
We used very similar risk-adjustment models for both octogenarians and those 65–79 years of age. Further,
between-group prevalence of major HF, risk factors were
also similar for both octogenarians and those 65–79 years
of age. Yet, despite a larger sample size and higher number
of events in those 65–79 years of age, pneumococcal vaccination had no association with incident HF or mortality. This
may suggest that the associations observed among the octogenarians are due to chance. However, prior studies have
reported that pneumococcal vaccination to be associated
with better CV outcomes.9,10 In one study, the use of pneumococcal vaccination was associated with higher risk of CV
outcomes among those <65 years of age, while there was
no such association among those ≥65 years of age.21,22
Taken together with the ﬁndings from our study, these ﬁndings suggest that there might exist a potential age-related
variation in the beneﬁt of pneumococcal vaccination. Oxidized low-density lipoproteins play an important role in atherogenesis, and antibodies against them may cause
regression of atherosclerosis.23,24 In laboratory animals,
pneumococcal vaccination has been shown to decrease atherosclerotic lesion.25 Preliminary ﬁndings from human studies suggest that pneumococcal vaccination may induce
antibodies against oxidized low-density lipoproteins.26 Although oxidized low-density lipoproteins are not known HF
risk factors, they have been shown to be associated with
other cardiovascular events.27
Pneumococcal disease is common among older adults, speciﬁcally among octogenarians,28,29 and pneumococcal vaccination is recommended for all adults ≥65 years of age.30
Findings from the current study suggest that this vaccination
might also lower the risk of HF and CV mortality among octogenarians. Prospective studies of pneumococcal vaccination in
octogenarians would be unethical as it would require delaying
vaccination until that age. However, if these ﬁndings can be
replicated in other octogenarian populations, this might provide an inexpensive tool for improving the health and outcomes of the fastest growing segment of the US population.
It will also provide additional rationale to increase the utilization of pneumococcal vaccination, which remains low, about
60% among adults ≥65 years of age in 2010.8
Our study has several limitations. As discussed earlier, an
important limitation of any observational study is the potential for bias due to unmeasured confounders, and ours is no
exception. We had no data on the time of pneumococcal vaccination. The 23-valent polysaccharide pneumococcal vaccine
was licenced in 1977 and has been reimbursed by Medicare
since 1981.31,32 Although utilization of pneumococcal vaccination has improved over the years,8 use was low in 1989
when participants were enrolled in the CHS. Octogenarians
are survivors, and the survival bias is likely to be more
ESC Heart Failure 2016; 3: 11–17
DOI: 10.1002/ehf2.12056
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pronounced among those with prior pneumococcal vaccination. However, despite accumulation of higher proportion of
susceptible patients, we observed a lower risk of incident
HF and cardiovascular events among these patients. It is possible that some of the octogenarians in the unvaccinated
group were vaccinated during follow-up or that recollection
of vaccination was inaccurate resulting in incorrect classiﬁcation. However, this would be expected to result in regression
dilution and underestimation of the true association.33 Finally, because ﬁndings of our study are hypothesis-generating
and do not provide mechanistic insights, they need to be
interpreted with caution.

growing segment of the population in developing nations
who also has the highest risk of HF.
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